| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -519.75% | -269.57% | -140.96% | -152.74% | -179.30% | -361.13% | -2029.86% | -2970.75% | -3220.12% | -2296.03% | -2182.69% | -3509.59% |
| EBITDA Margin | -511.43% | -263.63% | -135.86% | -148.65% | -173.74% | -345.19% | -1970.00% | -2855.88% | -3135.62% | -2249.34% | -2139.60% | -3438.73% |
| Net Margin | -511.90% | -303.67% | -138.14% | -137.95% | -15.06% | -894.31% | -2043.34% | -3013.97% | -3296.20% | -2369.00% | -2271.31% | -3710.88% |
| Current Ratio | 15.39 | 10.66 | 6.66 | 4.13 | 7.26 | 9.23 | 5.00 | 6.14 | 3.23 | 8.42 | 19.89 | 12.97 |
| Quick Ratio | 15.32 | 10.59 | 6.59 | 4.07 | 7.22 | 9.19 | 4.92 | 6.11 | 3.22 | 8.41 | 19.87 | 12.95 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -40.64% | -61.36% | -88.59% | -200.79% | -7.45% | -204.53% | 2379.39% | -167.19% | -242.42% | -85.95% | -44.37% | -48.81% |
| ROA | -32.91% | -42.26% | -32.03% | -47.58% | -3.20% | -59.43% | -109.69% | -82.11% | -114.35% | -59.65% | -36.03% | -36.64% |
| Asset Turnover | 0.06 | 0.14 | 0.23 | 0.34 | 0.21 | 0.07 | 0.05 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 |
| Book Value / Share | 3.49 | 1.99 | 1.06 | 0.43 | 1.07 | 1.25 | -0.08 | 0.94 | 0.91 | 2.10 | 3.85 | 5.51 |
Ocular Therapeutix Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye. It specializes in ophthalmology, particularly advancing treatments for retinal disorders such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR). The company's pipeline features AXPAXLI (OTX-TKI), a tyrosine kinase inhibitor delivered via intravitreal bioresorbable implant designed for extended durability, currently in late-stage Phase 3 clinical programs including the SOL-1 superiority trial and HELIOS registrational program. Ocular Therapeutix Inc. also markets DEXTENZA, a commercial intracanalicular insert for ocular pain and inflammation post-surgery. Additional candidates like OTX-TP target glaucoma and dry eye disease. Headquartered in Bedford, Massachusetts and founded in 2006, the company plays a key role in the retinal therapeutics market by leveraging bioresorbable hydrogel technology to improve patient outcomes and reduce treatment burden through sustained drug delivery systems.